Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Post by ferraridanon Apr 03, 2020 9:26am
218 Views
Post# 30875200

Response From IR

Response From IRCompletely disagree with Hydrocarbs.  Here is the response which is a whitewash.  It does not take into account the complete failure of management to manage trilogy 1/2.  Hiring consultants saying you're not well paid is easy.  Taking reponsibility for your failures is harder but more honest.


In terms of management and board compensation, the board, completely independent of management, brought in one of the top compensation firms in the life science industry, and they assembled a peer group compensation data set for benchmarking purposes.  That analysis showed that our management and the board are well below market in terms of cash compensation and stock options held.  Given that we are in cash preservation mode, the independent consultants recommended how to handle this year's annual grants, and the board followed their recommendations completely.
 
Everyone is working around the clock despite COVID-19, taking time away from their families.  They are all 100% committed to the success of CaPre. We look forward to providing further updates as soon as practical.
 
Regards,
Alexandra Botie
Senior Account Executive
Crescendo Communications, LLC
Office: (212) 671-1020 Ext: 305
Email: abotie@crescendo-ir.com
Website: www.crescendo-ir.com
 

Bullboard Posts